Viracta Therapeutics (Viracta Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of Jun. 07, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Viracta Therapeutics 5-Year Yield-on-Cost %?

Viracta Therapeutics's yield on cost for the quarter that ended in Mar. 2024 was 0.00.

The historical rank and industry rank for Viracta Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:

VIRX's 5-Year Yield-on-Cost % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Viracta Therapeutics's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Viracta Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viracta Therapeutics's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viracta Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Viracta Therapeutics's 5-Year Yield-on-Cost % falls into.

Viracta Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Viracta Therapeutics is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Viracta Therapeutics (NAS:VIRX) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Viracta Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Viracta Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Viracta Therapeutics (Viracta Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viracta Therapeutics Inc (NAS:VIRX) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

RYIS:Germany

Address

2533 South Coast Highway 101, Suite 210, Cardiff, CA, USA, 92007

Website

https://www.viracta.com

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants.

Executives

Mark Rothera	director, officer: President and CEO	C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
Daniel R. Chevallard	officer: Chief Executive Officer	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Darrel P. Cohen	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 S. COAST HWY 101, SUITE 210, CARDIFF CA 92007
Lisa Rojkjaer	officer: Chief Medical Officer	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Ivor Royston	director, officer: CEO & President	4401 WILSHIRE BLVD., SUITE 200, LOS ANGELES CA 90010
Jane Chung	director	C/O SUTRO BIOPHARMA, INC., 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO CA 94080
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Flavia Borellini	director	C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY CA 94063
Barry J. Simon	director	2533 SOUTH COAST HIGHWAY 101, SUITE 210, CARDIFF-BY-THE-SEA CA 92007
Stephen Rubino	director	C/O VIRACTA THERAPEUTICS, INC., 2533 SOUTH COAST HWY., STE. 210, CARDIFF CA 92007
Gur Roshwalb	director, 10 percent owner	C/O CELSUS THERAPEUTICS PLC, 24 WEST 40TH STREET, NEW YORK NY 10018
Roger Pomerantz	director	711 HARVEST HILL ROAD, CHALFONT PA 18914
Michael Huang	director	C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Amoon Growth Fund Limited Partnership	10 percent owner	34 YERUSHALAYIM RD., RAANANA L3 4350110
Thomas E Darcy	director	C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121